<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1182" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1182/" /><meta name="ncbi_pagename" content="PLP1 Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>PLP1 Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="PLP1 Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/12/19" /><meta name="citation_author" content="Nicole I Wolf" /><meta name="citation_author" content="Rosalina ML van Spaendonk" /><meta name="citation_author" content="Grace M Hobson" /><meta name="citation_author" content="John Kamholz" /><meta name="citation_pmid" content="20301361" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1182/" /><meta name="citation_keywords" content="Spastic Paraplegia 2 (SPG 2)" /><meta name="citation_keywords" content="Pelizaeus-Merzbacher Disease (PMD)" /><meta name="citation_keywords" content="Myelin proteolipid protein" /><meta name="citation_keywords" content="PLP1" /><meta name="citation_keywords" content="PLP1-Related Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="PLP1 Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Nicole I Wolf" /><meta name="DC.Contributor" content="Rosalina ML van Spaendonk" /><meta name="DC.Contributor" content="Grace M Hobson" /><meta name="DC.Contributor" content="John Kamholz" /><meta name="DC.Date" content="2019/12/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1182/" /><meta name="description" content="PLP1 disorders of central nervous system myelin formation include a range of phenotypes from Pelizaeus-Merzbacher disease (PMD) to spastic paraplegia 2 (SPG2). PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment; the findings progress to severe spasticity and ataxia. Life span is shortened. SPG2 manifests as spastic paraparesis with or without CNS involvement and usually normal life span. Intrafamilial variation of phenotypes can be observed, but the signs are usually fairly consistent within families. Heterozygous females may manifest mild-to-moderate signs of the disease." /><meta name="og:title" content="PLP1 Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="PLP1 disorders of central nervous system myelin formation include a range of phenotypes from Pelizaeus-Merzbacher disease (PMD) to spastic paraplegia 2 (SPG2). PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment; the findings progress to severe spasticity and ataxia. Life span is shortened. SPG2 manifests as spastic paraparesis with or without CNS involvement and usually normal life span. Intrafamilial variation of phenotypes can be observed, but the signs are usually fairly consistent within families. Heterozygous females may manifest mild-to-moderate signs of the disease." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1182/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/pmd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1182/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE896571DFC9378100000000003D0020.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1182_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1182_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/eds6/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cdg-1a/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1182_"><span class="title" itemprop="name"><i>PLP1</i> Disorders</span></h1><p class="contrib-group"><span itemprop="author">Nicole I Wolf</span>, MD, PhD, <span itemprop="author">Rosalina ML van Spaendonk</span>, PhD, <span itemprop="author">Grace M Hobson</span>, PhD, and <span itemprop="author">John Kamholz</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1182_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1182_ai__"><div class="contrib half_rhythm"><span itemprop="author">Nicole I Wolf</span>, MD, PhD<div class="affiliation small">Department of Child Neurology<br />Amsterdam University Medical Center<br />Amsterdam, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmumadretsma@flow.n" class="oemail">ln.cmumadretsma@flow.n</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Rosalina ML van Spaendonk</span>, PhD<div class="affiliation small">Department of Clinical Genetics<br />Amsterdam University Medical Center<br />Amsterdam, The Netherlands<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ln.cmumadretsma@ennevrev.r" class="oemail">ln.cmumadretsma@ennevrev.r</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Grace M Hobson</span>, PhD<div class="affiliation small">Nemours Biomedical Research<br />AI duPont Hospital for Children<br />Wilmington, Delaware<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.sruomen@nosbohg" class="oemail">gro.sruomen@nosbohg</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John Kamholz</span>, MD, PhD<div class="affiliation small">University of Iowa Hospitals &#x00026; Clinics<br />Iowa City, Iowa<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.awoiu@zlohmak-nhoj" class="oemail">ude.awoiu@zlohmak-nhoj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">June 15, 1999</span>; Last Update: <span itemprop="dateModified">December 19, 2019</span>.</p><p><em>Estimated reading time: 28 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="pmd.Summary" itemprop="description"><h2 id="_pmd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>PLP1</i> disorders of central nervous system myelin formation include a range of phenotypes from Pelizaeus-Merzbacher disease (PMD) to spastic paraplegia 2 (SPG2). PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment; the findings progress to severe spasticity and ataxia. Life span is shortened. SPG2 manifests as spastic paraparesis with or without CNS involvement and usually normal life span. Intrafamilial variation of phenotypes can be observed, but the signs are usually fairly consistent within families. Heterozygous females may manifest mild-to-moderate signs of the disease.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of a <i>PLP1</i> disorder is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> involving <i>PLP1</i>. The diagnosis of a <i>PLP1</i> disorder is usually established in a female with neurologic signs, a family history of a <i>PLP1</i> disorder, and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variant in <i>PLP1</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> A multidisciplinary team comprising specialists in neurology, physical medicine, orthopedics, pulmonary medicine, and gastroenterology is optimal for care. Treatment may include gastrostomy for individuals with severe dysphagia; antiepileptic drugs for seizures; and routine management of spasticity including physical therapy, exercise, medications (baclofen, diazepam, tizanidine), orthotics, and surgery for joint contractures. Individuals with scoliosis benefit from proper wheelchair seating and physical therapy; surgery may be required for severe scoliosis. Specialized education and assessments are generally necessary, and assistive communication devices may be helpful.</p><p><i>Prevention of secondary complications:</i> Proper wheelchair seating and physical therapy may help prevent scoliosis; speech and swallowing evaluations can identify patients who may need a feeding tube for safer and/or adequate nutrition and hydration.</p><p><i>Surveillance</i>: Semiannual to annual neurologic and physical medicine evaluations during childhood to monitor developmental progress, spasticity, and orthopedic complications.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>PLP1</i> disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. <i>De novo</i> pathogenic variants have been reported.</p><ul><li class="half_rhythm"><div>If the mother has a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting the variant in each pregnancy is 50%. Males who inherit the variant will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; females who inherit the variant may manifest mild-to-moderate signs of the disorder. (<i>PLP1</i> alleles that cause relatively mild neurologic signs in affected males are more likely to be associated with neurologic manifestations in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females.)</div></li><li class="half_rhythm"><div>Males with the PMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> do not reproduce; males with SPG2 phenotype transmit the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to all of their daughters and none of their sons.</div></li></ul><p>Prenatal testing for a pregnancy at increased risk is possible if the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known.</p></div></div><div id="pmd.GeneReview_Scope"><h2 id="_pmd_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="pmd.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pmd.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLP1</i> Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_pmd.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Pelizaeus-Merzbacher disease (PMD)</div></li><li class="half_rhythm"><div><i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome</div></li><li class="half_rhythm"><div>Hypomyelination of early myelinating structures (HEMS)</div></li><li class="half_rhythm"><div>Spastic paraplegia 2 (SPG2)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#pmd.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="pmd.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#pmd.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="pmd.Diagnosis"><h2 id="_pmd_Diagnosis_">Diagnosis</h2><div id="pmd.Suggestive_Findings"><h3>Suggestive Findings</h3><p>A <i>PLP1</i> disorder <b>should be suspected</b> in an individual with the following clinical and imaging features.</p><div id="pmd.Clinical_features"><h4>Clinical features</h4><ul><li class="half_rhythm"><div>Infantile or early childhood onset of nystagmus, hypotonia, and cognitive impairment</div></li><li class="half_rhythm"><div>Progression to severe spasticity and ataxia</div></li><li class="half_rhythm"><div>Spastic paraparesis with or without CNS involvement</div></li><li class="half_rhythm"><div>Spastic urinary bladder</div></li></ul></div><div id="pmd.Imaging_features"><h4>Imaging features</h4><p><b>Magnetic resonance imaging (MRI)</b> (T<sub>2</sub>-weighted or fluid-attenuated inversion recovery (FLAIR) scans):</p><ul><li class="half_rhythm"><div class="half_rhythm">Diffusely increased T<sub>2</sub> signal intensity in the white matter of the cerebral hemispheres, cerebellum, and brain stem, consistent with hypomyelination [<a class="bk_pop" href="#pmd.REF.steenweg.2010.2971">Steenweg et al 2010</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Slowly progressive volume loss in older children [<a class="bk_pop" href="#pmd.REF.sarret.2016.706">Sarret et al 2016</a>].</div><div class="half_rhythm">Note: Because the bulk of myelination normally occurs during the first two years of life, the T<sub>2</sub>-weighted MRI images may not show definitive abnormalities until a child is at least age one or two years. However, a normal newborn should have myelination-related T<sub>1</sub> and T<sub>2</sub> signal changes in the pons and cerebellum, and a normal three-month-old infant should have evidence of myelination in the posterior limb of the internal capsule, in the splenium of the corpus callosum, and in optic radiations [<a class="bk_pop" href="#pmd.REF.barkovich.2005.311">Barkovich 2005</a>]. Absence of these early changes should raise the consideration for PMD or other hypomyelinating disorders.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hypomyelination of early myelinating structures (HEMS).</b> Individuals with HEMS show hypomyelinated structures which normally myelinate early in development, such as optic radiation and brain stem, whereas other white matter structures are better myelinated [<a class="bk_pop" href="#pmd.REF.kevelam.2015.648">Kevelam et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Spastic paraplegia 2 (SPG2).</b> People with the SPG2 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> show less severe abnormalities on MRI scanning; they may have patchy abnormalities on T<sub>2</sub>-weighted scans or more diffuse leukoencephalopathy [<a class="bk_pop" href="#pmd.REF.hodes.1999.132">Hodes et al 1999</a>].</div></li></ul><p><b>Magnetic resonance spectroscopy (MRS)</b> may show reduced white matter N-acetyl aspartate (NAA) levels, especially in individuals with the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome [<a class="bk_pop" href="#pmd.REF.bonavita.2001.785">Bonavita et al 2001</a>, <a class="bk_pop" href="#pmd.REF.garbern.2002.1033">Garbern &#x00026; Hobson 2002</a>, <a class="bk_pop" href="#pmd.REF.plecko.2003.127">Plecko et al 2003</a>]. In contrast, individuals with <i>PLP1</i> duplications may have increased white matter NAA levels.</p></div></div><div id="pmd.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of a <i>PLP1</i> disorder:</p><ul><li class="half_rhythm"><div><b>Is established in a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b> by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PLP1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1182/table/pmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpmdTmoleculargenetictestingusedin" rid-ob="figobpmdTmoleculargenetictestingusedin">Table 1</a>);</div></li><li class="half_rhythm"><div><b>Is usually established in a female</b> with neurologic signs, a family history of <i>PLP1</i> disorder, and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>PLP1</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1182/table/pmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpmdTmoleculargenetictestingusedin" rid-ob="figobpmdTmoleculargenetictestingusedin">Table 1</a>).</div></li></ul><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>), and <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>), depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>PLP1</i> disorders is broad, individuals with the distinctive findings described in <a href="#pmd.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#pmd.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with hypotonia, cognitive impairment, and/or spastic paraparesis are more likely to be diagnosed using genomic testing (see <a href="#pmd.Option_2">Option 2</a>).</p><div id="pmd.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of a <i>PLP1</i> disorder, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a></b>, <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</b> Multiplex ligation-dependent probe amplification (MLPA), targeted microarray, <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a> (qPCR), or <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> analysis should be considered first to identify a <i>PLP1</i> deletion/duplication.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> If a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> is not identified, <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> should be considered. Sequence analysis of <i>PLP1</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants.</div><div class="half_rhythm">Note: In individuals with HEMS, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 3 should be performed if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3B.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>PLP1</i> and other genes of interest (see <a href="#pmd.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1182/table/pmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figpmdTmoleculargenetictestingusedin" rid-ob="figobpmdTmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="pmd.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by motor and cognitive impairment, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="pmd.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>PLP1</i> Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic<br />Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLP1</i></td><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>3</sup></td><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60-70%&#x000a0;<sup>4,&#x000a0;5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>7,&#x000a0;8</sup></td><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%-40%</td></tr><tr><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">See footnote 9</td><td headers="hd_h_pmd.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;1%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pmd.TF.1.1"><p class="no_margin">See <a href="/books/NBK1182/#pmd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="pmd.TF.1.2"><p class="no_margin">See <a href="#pmd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="pmd.TF.1.3"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include multiplex ligation-dependent probe amplification (MLPA), a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray, <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, and long-range PCR designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>4. </dt><dd><div id="pmd.TF.1.4"><p class="no_margin">The majority of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> dosage changes are tandem duplications occurring in Xq22, which include all of <i>PLP1</i>. In rare instances, the duplicated region can be inserted at some distance from Xq22; four insertions have been reported: at Xp22, Xq28 [<a class="bk_pop" href="#pmd.REF.woodward.1998.a394">Woodward et al 1998</a>, <a class="bk_pop" href="#pmd.REF.hodes.2000.14">Hodes et al 2000</a>], and 19qtel [<a class="bk_pop" href="#pmd.REF.inoue.2002.838">Inoue et al 2002</a>]; and in the Y <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> [<a class="bk_pop" href="#pmd.REF.woodward.2005.966">Woodward et al 2005</a>]. Triplication, partial triplication, and quintuplication of <i>PLP1</i> also occur [<a class="bk_pop" href="#pmd.REF.boespflugtanguy.1994.461">Boespflug-Tanguy et al 1994</a>, <a class="bk_pop" href="#pmd.REF.woodward.1998.a394">Woodward et al 1998</a>, <a class="bk_pop" href="#pmd.REF.wolf.2005.743">Wolf et al 2005</a>, <a class="bk_pop" href="#pmd.REF.combes.2006.31">Combes et al 2006</a>]. In <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> females, <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> often occurs with complex chromosomal rearrangements.</p></div></dd><dt>5. </dt><dd><div id="pmd.TF.1.5"><p class="no_margin">Whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions of <i>PLP1</i> occur in fewer than 2% of those with the Pelizaeus-Merzbacher disease <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#pmd.REF.raskind.1991.1355">Raskind et al 1991</a>; <a class="bk_pop" href="#pmd.REF.boespflugtanguy.1994.461">Boespflug-Tanguy et al 1994</a>; <a class="bk_pop" href="#pmd.REF.inoue.2002.838">Inoue et al 2002</a>; Shaffer, unpublished observations]. <a class="bk_pop" href="#pmd.REF.inoue.2002.838">Inoue et al [2002]</a> determined that the individual originally described with a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> has a complex rearrangement with both a deletion of <i>PLP1</i> and an inverted <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of a more distal portion of the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> at the deletion junction. In addition, this individual has <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> of a region distal of <i>PLP1</i> [<a class="bk_pop" href="#pmd.REF.hobson.2002.2045a">Hobson et al 2002</a>, <a class="bk_pop" href="#pmd.REF.lee.2007.1235">Lee et al 2007</a>]. Partial <i>PLP1</i> deletion has also been reported [<a class="bk_pop" href="#pmd.REF.combes.2006.31">Combes et al 2006</a>].</p></div></dd><dt>6. </dt><dd><div id="pmd.TF.1.6"><p class="no_margin">Depending on the method used, larger <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> events may be detected. Position effect of a duplication identified by <a class="def" href="/books/n/gene/glossary/def-item/fish/">FISH</a> that was near but did not include <i>PLP1</i> has been invoked as the cause of the neurologic syndrome in a man with spastic paraplegia [<a class="bk_pop" href="#pmd.REF.lee.2006.398">Lee et al 2006</a>].</p></div></dd><dt>7. </dt><dd><div id="pmd.TF.1.7"><p class="no_margin">Sequence analysis which should include analysis of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 3B detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>8. </dt><dd><div id="pmd.TF.1.8"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>9. </dt><dd><div id="pmd.TF.1.9"><p class="no_margin">An inversion of the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> with a breakpoint 70 kbp upstream of <i>PLP1</i>, identified by chromosome analysis, was proposed to disrupt <i>PLP1</i> expression through position effect in a child with PMD-like syndrome [<a class="bk_pop" href="#pmd.REF.muncke.2004.e121">Muncke et al 2004</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="pmd.Clinical_Characteristics"><h2 id="_pmd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="pmd.Clinical_Description"><h3>Clinical Description</h3><div id="pmd.Males"><h4>Males</h4><p>Pelizaeus-Merzbacher disease (PMD) and <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> spastic paraplegia 2 (SPG2) are at opposite ends of a clinical spectrum of disease caused by pathogenic variants in <i>PLP1</i>, which results in defective central nervous system (CNS) myelination. PMD and SPG2 have been observed in different males within the same family [<a class="bk_pop" href="#pmd.REF.hodes.1993.383">Hodes et al 1993</a>, <a class="bk_pop" href="#pmd.REF.sistermans.1998.1749">Sistermans et al 1998</a>].</p><p><a class="bk_pop" href="#pmd.REF.boulloche.1986.233">Boulloche &#x00026; Aicardi [1986]</a>, <a class="bk_pop" href="#pmd.REF.hodes.1993.383">Hodes et al [1993]</a>, and <a class="bk_pop" href="#pmd.REF.cailloux.2000.837">Cailloux et al [2000]</a> have summarized the clinical features of their series of individuals with PMD. The phenotypes in this spectrum cannot be neatly categorized into distinct syndromes but are summarized using designations frequently encountered in the medical literature (<a class="figpopup" href="/books/NBK1182/table/pmd.T.spectrum_of_plp1_disorders/?report=objectonly" target="object" rid-figpopup="figpmdTspectrumofplp1disorders" rid-ob="figobpmdTspectrumofplp1disorders">Table 2</a>).</p><div id="pmd.T.spectrum_of_plp1_disorders" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Spectrum of <i>PLP1</i> Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.T.spectrum_of_plp1_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.T.spectrum_of_plp1_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age of Onset</th><th id="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic Findings</th><th id="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ambulation</th><th id="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Speech</th><th id="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age at Death</th></tr></thead><tbody><tr><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe "connatal" PMD</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonatal period</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nystagmus at birth; pharyngeal weakness; stridor; hypotonia; severe spasticity; &#x000b1; seizures; cognitive impairment</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Never achieved</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent, but nonverbal communication &#x00026; speech comprehension possible</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Infancy to 3rd decade</td></tr><tr><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Classic PMD</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1st 5 yrs</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nystagmus in 1st 2 mos; initial hypotonia; spastic quadriparesis; ataxia titubation; &#x000b1; dystonia, athetosis; cognitive impairment</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">W/assistance if achieved; lost in childhood/<br />adolescence</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually present</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3rd-7th decade</td></tr><tr><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1st 5 yrs</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No nystagmus; mild spastic quadriparesis; ataxia; peripheral neuropathy; mild-to-moderate cognitive impairment</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present; usually worsens after adolescence</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5th-7th decade</td></tr><tr><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complicated SPG (SPG2) &#x00026; HEMS</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1st 5 yrs</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nystagmus; ataxia; autonomic dysfunction&#x000a0;<sup>1</sup>; spastic gait; little or no cognitive impairment</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4th-7th decade</td></tr><tr><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Uncomplicated SPG (SPG2)</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually 1st 5 yrs; may be 3rd-4th decade</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Autonomic dysfunction&#x000a0;<sup>1</sup>; spastic gait; normal cognition</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Present</td><td headers="hd_h_pmd.T.spectrum_of_plp1_disorders_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">HEMS = hypomyelination of early myelinating structures; PMD = Pelizaeus-Merzbacher disease; SPG = spastic paraplegia</p></div></dd><dt>1. </dt><dd><div id="pmd.TF.2.1"><p class="no_margin">Spastic urinary bladder</p></div></dd></dl></div></div></div><p><b>Severe or "connatal" PMD</b> is apparent at birth or in the first few weeks of life. Findings include pendular nystagmus, hypotonia, and stridor. Seizures may develop in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants, and motor deficits are severe (e.g., infants do not gain head control).</p><p>Later, children with severe PMD may have short stature and poor weight gain. Hypotonia later evolves into spasticity of the extremities that is usually quite severe. Children do not walk or develop effective use of the upper limbs. Verbal expression is severely limited, but comprehension may be significant. Swallowing difficulties may require feeding tube placement.</p><p>Affected children may die during infancy or childhood, usually of aspiration; with attentive care, they may live into the third decade or longer.</p><p><b>Classic PMD.</b> Males with classic PMD usually develop nystagmus, which may not be recognized until several months of age; in rare cases, nystagmus does not develop. Affected children have hypotonia and develop titubation (tremor of the head and neck), ataxia, and spastic quadriparesis beginning in the first five years; they usually have some purposeful voluntary control of the arms. If acquired, ambulation usually requires assistive devices such as crutches or a walker; ambulation is generally lost as spasticity increases during later childhood or adolescence.</p><p>Cognitive abilities are impaired, but exceed those of the more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children; language and speech usually develop. Extrapyramidal abnormalities, such as dystonic posturing and athetosis, may occur.</p><p>Survival into the sixth or seventh decade has been observed.</p><p><b>A transitional form,</b> intermediate in onset and severity to the connatal and classic forms of PMD, has also been defined.</p><p><b><i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome</b> is distinguished by the absence of nystagmus and the presence of relatively mild spastic quadriparesis that mostly affects the legs, with ataxia and mild multifocal demyelinating peripheral neuropathy. Those with the <i>PLP1</i> null syndrome generally ambulate better than those with classic PMD but may progress more rapidly because of degeneration of axons, inferred on the basis of magnetic resonance spectroscopy, which demonstrates reduced levels of white matter N-acetyl aspartate [<a class="bk_pop" href="#pmd.REF.garbern.2002.551">Garbern et al 2002</a>].</p><p><b>Complicated spastic paraparesis (SPG2) and hypomyelination of early myelinating structures (HEMS)</b> often include autonomic dysfunction (e.g., spastic urinary bladder), ataxia, and nystagmus. A clear distinction cannot be drawn on objective criteria between complicated spastic paraplegia and relatively mild PMD (e.g., <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome).</p><p><b>Pure spastic paraparesis (SPG2)</b> does not, by definition, include other significant CNS signs, although autonomic dysfunction, such as spastic urinary bladder, may also occur. Life span is normal.</p><p>Males with SPG2 have reproduced; males with the PMD <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have not.</p></div><div id="pmd.Neurophysiologic_Studies"><h4>Neurophysiologic Studies</h4><p>Visual, auditory, and somatosensory evoked potential testing show normal-to-near-normal latencies of the peripheral component of the respective sensory modality, but severely prolonged or absent central latencies.</p><p>Except in families with <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles or pathogenic variants affecting the <i>PLP1</i>-specific region or some <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants [<a class="bk_pop" href="#pmd.REF.shy.2003.354">Shy et al 2003</a>, <a class="bk_pop" href="#pmd.REF.vaursbarri_re.2003.769">Vaurs-Barri&#x000e8;re et al 2003</a>], peripheral nerve conduction studies are normal. When peripheral neuropathy is present, it is mild in comparison to the CNS disorder, and is characterized by mild slowing of conduction velocities that may be more pronounced across those regions of a limb susceptible to compression, such as the wrist and elbow.</p></div><div id="pmd.Heterozygous_Females"><h4>Heterozygous Females</h4><p>Women with a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may or may not have symptoms. Several investigators have observed that in families with severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> women are unlikely to have clinical manifestations of a <i>PLP1</i> disorder, whereas in families with mildly affected males, the heterozygous women are more likely to have symptoms [<a class="bk_pop" href="#pmd.REF.keogh.2017.451">Keogh et al 2017</a>]. Thus, an inverse relationship exists between the severity of manifestations in males and the likelihood of heterozygous females having neurologic signs.</p><p>The risk to <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females of developing neurologic signs is greatest in families in which <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males have a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome, followed by those in which affected males have an SPG2 syndrome or HEMS [<a class="bk_pop" href="#pmd.REF.hurst.2006.371">Hurst et al 2006</a>]. The risk of developing neurologic signs is lowest in heterozygous females with a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>, who usually have favorably skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> [<a class="bk_pop" href="#pmd.REF.woodward.2000.449">Woodward et al 2000</a>].</p><p>The following explanation is offered:</p><ul><li class="half_rhythm"><div>Alleles associated with a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> cause apoptosis (cell death) of oligodendrocytes (the cells that make myelin in the CNS) during early childhood. In <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, the oligodendrocytes that express the mutated <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> on the active X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> undergo apoptosis early in life but are replaced over time by oligodendrocytes that express the normal <i>PLP1</i> allele on the active X chromosome. Thus, females who carry a severe <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may develop neurologic signs because of skewed inactivation of the X chromosome with the normal <i>PLP1</i> allele (as with other <a class="def" href="/books/n/gene/glossary/def-item/x-linked-recessive/">X-linked recessive</a> disorders) or may have transient signs (while the oligodendrocytes expressing the mutated <i>PLP1</i> are still present) that abate as the degenerating oligodendrocytes are replaced by those expressing the normal <i>PLP1</i> allele [<a class="bk_pop" href="#pmd.REF.inoue.2001.747">Inoue et al 2001</a>].</div></li><li class="half_rhythm"><div>Alleles associated with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in males do not cause apoptosis of oligodendrocytes. In <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females, abnormal oligodendrocytes persist and can cause neurologic signs [<a class="bk_pop" href="#pmd.REF.sivakumar.1999.680">Sivakumar et al 1999</a>].</div></li></ul><p><a class="bk_pop" href="#pmd.REF.hurst.2006.371">Hurst et al [2006]</a> analyzed families with SPG2 or PMD and provided statistical support for the inverse correlation between the severity of phenotypes in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males and their <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> relatives. These observations have important implications for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> and are discussed in <a href="#pmd.Risk_to_Family_Members">Risk to Family Members</a>, <b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>.</p><p>Manifesting heterozygotes are usually not index cases, but rather are identified in the course of evaluating the relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male.</p><p>Females with PMD have been described. This is thought to be due to unfavorable X inactivation in the brain [<a class="bk_pop" href="#pmd.REF.scala.2019.268">Scala et al 2019</a>]. In some, there was considerable improvement of signs and symptoms after infancy. One female with classic PMD was found to have an <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of an extra copy of <i>PLP1</i> at <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 1p36 [<a class="bk_pop" href="#pmd.REF.masliahplanchon.2015.77">Masliah-Planchon et al 2015</a>]. Additional complex chromosome rearrangements in females with PMD have been described [<a class="bk_pop" href="#pmd.REF.ida.2003.557">Ida et al 2003</a>, <a class="bk_pop" href="#pmd.REF.yiu.2009.2171">Yiu et al 2009</a>].</p></div></div><div id="pmd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Some <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> exist.</p><p>Most individuals with <i>PLP1</i> duplications have classic PMD; however, some are classified as having connatal PMD and may have three or more copies of the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> [<a class="bk_pop" href="#pmd.REF.wolf.2005.743">Wolf et al 2005</a>]. Variation in the extent of <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> or location(s) of the breakpoints or reinsertion sites may account for clinical variability.</p><p>The most severe clinical syndromes are typically caused by <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants (especially nonconservative amino acid substitutions) and other <i>PLP1</i> single-nucleotide variants or indels.</p><p>The milder spastic paraplegia syndrome is most often caused by conservative amino acid substitutions in presumably less critical regions of the protein. The locations of these pathogenic variants do not provide a clear correlation between amino acid position and clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. However, pathogenic variants in the <i>PLP1</i>-specific <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> encoded by amino acid residues 117-151 and in <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 3 tend to cause less severe syndromes [<a class="bk_pop" href="#pmd.REF.cailloux.2000.837">Cailloux et al 2000</a>, <a class="bk_pop" href="#pmd.REF.taube.2014.5464">Taube et al 2014</a>, <a class="bk_pop" href="#pmd.REF.kevelam.2015.648">Kevelam et al 2015</a>] (see <a href="#pmd.Molecular_Genetics">Molecular Genetics</a>).</p><p>Although PMD has classically been regarded as a strictly CNS disorder, those with <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <i>PLP1</i> variants, including <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>PLP1</i> [<a class="bk_pop" href="#pmd.REF.raskind.1991.1355">Raskind et al 1991</a>], a <a class="def" href="/books/n/gene/glossary/def-item/frameshift-variant/">frameshift variant</a>, and a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant affecting the initiation codon do develop a relatively mild demyelinating peripheral neuropathy, demonstrating that myelin proteolipid protein (PLP1) and/or DM20 (an alternatively spliced transcript; see following paragraph and <a href="#pmd.Molecular_Genetics">Molecular Genetics</a>) does indeed function in the peripheral nervous system as well as in the CNS. Furthermore, the null <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has less severe CNS signs than those seen with the more typical forms of PMD. The null phenotype is associated with length-dependent degeneration of major central motor and sensory tracts and reduced levels of N-acetyl aspartate in cerebral white matter.</p><p>Peripheral neuropathy as well as a relatively mild CNS syndrome results from pathogenic variants that affect only the <i>PLP1</i>-specific region [<a class="bk_pop" href="#pmd.REF.shy.2003.354">Shy et al 2003</a>] (see <a href="#pmd.Molecular_Genetics">Molecular Genetics</a>). The CNS syndrome can be milder than that observed in individuals with the <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div><div id="pmd.Penetrance"><h3>Penetrance</h3><p><i>PLP1</i> pathogenic variants are believed to be completely penetrant in males.</p></div><div id="pmd.Nomenclature"><h3>Nomenclature</h3><p>Pelizaeus-Merzbacher disease is also known as sudanophilic or orthochromatic leukodystrophy.</p><p>Proteolipid protein 1 was previously called proteolipid protein. After discovery of a similar <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that is predominantly expressed in gut, numerical designation was added.</p><p>Note also that the older literature usually begins numbering of the amino acids with the glycine encoded by codon 2, since the initiation methionine is cleaved post-translationally.</p></div><div id="pmd.Prevalence"><h3>Prevalence</h3><p>In the US, the prevalence of PMD in the population is estimated at 1:200,000 to 1:500,000.</p><p>In a survey of leukodystrophies in Germany, the incidence of PMD was approximately 0.13:100,000 live births [<a class="bk_pop" href="#pmd.REF.heim.1997.475">Heim et al 1997</a>].</p><p><a class="bk_pop" href="#pmd.REF.seeman.2003.95">Seeman et al [2003]</a> reported that in the Czech Republic <i>PLP1</i> pathogenic variants were detected in 1:90,000 births. While this may reflect a situation particular to the Czech Republic, it suggests that the prevalence of PMD may be higher than is generally recognized.</p></div></div><div id="pmd.Genetically_Related_Allelic_Disorder"><h2 id="_pmd_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>PLP1</i>.</p></div><div id="pmd.Differential_Diagnosis"><h2 id="_pmd_Differential_Diagnosis_">Differential Diagnosis</h2><p>Individuals with <i>PLP1</i> disorders are often initially diagnosed with cerebral palsy or static encephalopathy.</p><div id="pmd.PelizaeusMerzbacher_Disease_PMD"><h3>Pelizaeus-Merzbacher Disease (PMD)</h3><p>The combination of nystagmus within the first two years of life, initial hypotonia, and abnormal white matter changes on the brain MRI (e.g., abnormal signal in the posterior limbs of the internal capsule, the middle, and superior cerebellar peduncles and the medial and lateral lemnisci, all of which should be myelinated in a normal newborn) should suggest the diagnosis of PMD, especially if the family history is consistent with an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder. In a recent survey of children with inherited diseases of white matter identified by neuroimaging, 7.4% had PMD, the second most common cause of leukodystrophy [<a class="bk_pop" href="#pmd.REF.bonkowsky.2010.718">Bonkowsky et al 2010</a>], suggesting that the disease is relatively common.</p><p>Approximately 20% of males with clinical findings consistent with a <i>PLP1</i> disorder do not have identifiable pathogenic variants in <i>PLP1</i>. Pathogenic variants in additional genes have been identified in individuals with a PMD-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and hypomyelination on brain MRI (see <a class="figpopup" href="/books/NBK1182/table/pmd.T.genes_of_interest_in_the_different/?report=objectonly" target="object" rid-figpopup="figpmdTgenesofinterestinthedifferent" rid-ob="figobpmdTgenesofinterestinthedifferent">Table 3</a>).</p><p><b>Hypomyelination</b> occurs in several disorders with clinical phenotypes distinct from PMD. <a href="https://www.ncbi.nlm.nih.gov/books/NBK99167/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">4H leukodystrophy</a> is the most frequent hypomyelinating disorder after PMD, individuals with 4H leukodystrophy usually do not have nystagmus, ataxia is prominent, and spasticity is mild or not present [<a class="bk_pop" href="#pmd.REF.wolf.2014.134">Wolf et al 2014</a>]. Oculodentodigital dysplasia presents sometimes in adulthood, with a SPG-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>; nystagmus is usually not present [<a class="bk_pop" href="#pmd.REF.harting.2019.903">Harting et al 2019</a>]. (For MRI characteristics and differential diagnosis of hypomyelination see also <a class="bk_pop" href="#pmd.REF.steenweg.2010.2971">Steenweg et al [2010]</a> and <a class="bk_pop" href="#pmd.REF.van_der_knaap.2019.962">van der Knaap et al [2019]</a>).</p><div id="pmd.T.genes_of_interest_in_the_different" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Genes of Interest in the Differential Diagnosis of Pelizaeus-Merzbacher Disease (PMD)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.T.genes_of_interest_in_the_different/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.T.genes_of_interest_in_the_different_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Gene(s)&#x000a0;<sup>1</sup></th><th id="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Disorder&#x000a0;<sup>2</sup></th><th id="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4" id="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Overlapping w/PMD</th><th headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4" id="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" scope="col" rowspan="1" colspan="1" style="background-color:rgb(242,242,242);text-align:left;vertical-align:middle;">Distinguishing from PMD</th></tr></thead><tbody><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>AIFM1</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelination w/spondyloepiphyseal dysplasia&#x000a0;<sup>3</sup></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spondyloepiphyseal dysplasia</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DARS1</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelination w/brain stem &#x00026; spinal cord involvement &#x00026; severe leg spasticity (OMIM <a href="https://omim.org/entry/615281" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615281</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity/ataxia; nystagmus; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Characteristic involvement of brain stem &#x00026; spinal cord structures on MRI</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>EPRS1</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelinating leukodystrophy 15 (OMIM <a href="https://omim.org/entry/617951" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617951</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity/ataxia; nystagmus; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Posterior columns may be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> on MRI</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FAM126A</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hypo-mcc/">Hypomyelination &#x00026; congenital cataract</a></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity/ataxia; nystagmus; demyelinating peripheral neuropathy; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Congenital cataract; areas w/both T<sub>2</sub>-weighted hyperintensity &#x00026; T<sub>1</sub>-weighted hypointensity</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GJA1</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Oculodentodigital dysplasia (OMIM <a href="https://omim.org/entry/164200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">164200</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild symptoms, sometimes diagnosis only in adulthood; syndactyly; ocular abnormalities; <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> signs; prominent spastic bladder</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GJC2</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pmld1/">Pelizaeus-Merzbacher-like disease 1</a></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity/ataxia; nystagmus; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Epilepsy is frequent. More pronounced hypomyelination in subcortical white matter; prominent brain stem involvement</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HSPD1</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelinating leukodystrophy 4 (OMIM <a href="https://omim.org/entry/612233" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612233</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Resembles severe PMD&#x000a0;<sup>4</sup>; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acquired microcephaly; severe epilepsy</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NKX6-2</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/nkx6-2-spax/"><i>NKX6-2</i> disorder</a></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity/ataxia; nystagmus; hypotonia; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe early dystonia, early-onset (transitory) respiratory failure</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>POLR3A</i><br /><i>POLR3B</i><br /><i>POLR3K</i><br /><i>POLR1C</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/pol3-leuk/">4H leukodystrophy</a> (hypomyelination, hypodontia, &#x00026; hypogonadotropic hypogonadism)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myopia (no nystagmus); hypodontia; hypogonadotropic hypogonadism; early cerebellar atrophy; better myelination of posterior limb of the internal capsule, ventrolateral thalamus &#x00026; optic radiation</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RARS1</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelinating leukodystrophy 9 (OMIM <a href="https://omim.org/entry/616140" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616140</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity/ataxia; nystagmus; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No specific distinguishing features; in severe cases, microcephaly &#x00026; early epileptic encephalopathy</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC16A2</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/thctd/">MCT8-specific thyroid hormone cell-membrane transporter deficiency</a> (Allan-Hernon-Dudley syndrome)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonatal hypotonia, nystagmus, severe DD</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191; serum T3 concentration; &#x02193; serum reverse T3 concentration; MRI shows (severely) delayed myelination, but not hypomyelination</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC17A5</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Salla disease (see <a href="/books/n/gene/issd/">Free Sialic Acid Storage Disorders</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x000b1; hypotonia, nystagmus, DD; in severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, diffusely abnormal myelination w/uniformly hyperintense white matter on T<sub>2</sub>-weighted images; in less severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, delayed myelination, occurring mainly in the periventricular regions</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizures are more common than in PMD, but children w/Salla disease are more likely to show improvement; MRI shows thin corpus callosum early on.</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SOX10</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">PCWH syndrome (OMIM <a href="https://omim.org/entry/609136" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">609136</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Peripheral <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hypomyelinating neuropathy; Waardenburg-Hirschsprung syndrome</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TMEM106B</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypomyelinating leukodystrophy 16 (OMIM <a href="https://omim.org/entry/617964" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">617964</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nystagmus; hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild clinical presentation (mild ataxia, mild cognitive impairment)</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TMEM63A</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Transient hypomyelination&#x000a0;<sup>5</sup></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Initially indistinguishable from PMD (<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> nystagmus, hypotonia, hypomyelination)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Positive evolution w/normalization of development &#x00026; MRI findings</td></tr><tr><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TUBB4A</i></td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">H<a href="/books/n/gene/x-ald/">ypomyelination</a> w/atrophy of basal ganglia &#x00026; cerebellum (see <a href="https://www.ncbi.nlm.nih.gov/books/NBK395611/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri"><i>TUBB4A</i>-Related Leukodystrophy</a>)</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spasticity, nystagmus (not invariable); hypomyelination</td><td headers="hd_h_pmd.T.genes_of_interest_in_the_different_1_1_1_4 hd_h_pmd.T.genes_of_interest_in_the_different_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Usually atrophy of the basal ganglia &#x00026; cerebellum</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; DD = developmental delay; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; PCWH = peripheral demyelinating neuropathy, central dysmyelination, Waardenburg syndrome, and Hirschsprung disease; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="pmd.TF.3.1"><p class="no_margin">Genes are listed alphabetically.</p></div></dd><dt>2. </dt><dd><div id="pmd.TF.3.2"><p class="no_margin">Other leukodystrophies should also be considered; see <a href="/books/n/gene/leukodys-ov/">Leukodystrophy Overview</a>.</p></div></dd><dt>3. </dt><dd><div id="pmd.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#pmd.REF.miyake.2017.185">Miyake et al [2017]</a></p></div></dd><dt>4. </dt><dd><div id="pmd.TF.3.4"><p class="no_margin">Described in an Israeli Bedouin family</p></div></dd><dt>5. </dt><dd><div id="pmd.TF.3.5"><p class="no_margin"><a class="bk_pop" href="#pmd.REF.yan.2019.996">Yan et al [2019]</a></p></div></dd></dl></div></div></div></div><div id="pmd.Spastic_Paraplegia_2_SPG2"><h3>Spastic Paraplegia 2 (SPG2)</h3><p>To date, more than 80 genetic types of hereditary spastic paraplegia have been defined. See the <a href="/books/n/gene/hsp/">Hereditary Spastic Paraplegia Overview</a> for clinical characteristics of other hereditary spastic paraplegias.</p></div></div><div id="pmd.Management"><h2 id="_pmd_Management_">Management</h2><div id="pmd.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with a <i>PLP1</i> disorder, the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Physical examination to determine extent and severity of respiratory and feeding difficulties, weakness, hypotonia, spasticity, scoliosis, ataxia, visual impairment, cognitive impairment, contractures, joint dislocations, and ambulation</div></li><li class="half_rhythm"><div>In infants and children, developmental assessment to determine capabilities and needs for cognitive, physical, and other symptomatic therapies</div></li><li class="half_rhythm"><div>Brain MRI (more helpful age &#x02265;9 months) to determine severity of myelination abnormalities; in older children and adults, magnetic resonance spectroscopy to ascertain axonal dysfunction</div></li><li class="half_rhythm"><div>Assessment of peripheral nerve function using NCV to presumptively identify individuals with the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome (probably reliable only after age 4 years)</div></li><li class="half_rhythm"><div>Family history to identify other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at-risk individuals</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="pmd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>A multidisciplinary team comprising specialists in neurology, physical medicine, orthopedics, pulmonary medicine, and gastroenterology is optimal for care [<a class="bk_pop" href="#pmd.REF.van_haren.2015.516">Van Haren et al 2015</a>].</p><p>Early attention to swallowing difficulties and airway protection, especially in the most severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, is important. Those with severe dysphagia may require feeding by gastrostomy.</p><p>Seizures are usually restricted to individuals with the most severe (connatal) syndrome and although they may not always be associated with electroencephalographic evidence for epileptiform waveforms, they generally respond to antiepileptic drugs such as carbamazepine.</p><p>Spasticity management may include physical therapy and exercises, including regular stretching exercises. Antispasticity medications such as baclofen (including intrathecal administration), diazepam, and tizanidine may be helpful, especially in combination with physical therapy, exercise, orthotics, and other assistive devices. In advanced cases, surgery to release joint contractures may be required.</p><p>Severe scoliosis may result in pulmonary compromise as well as discomfort, especially with position changes, and necessitate corrective surgery to preserve pulmonary function. Proper seating (especially wheelchair) and physical therapy may reduce or prevent the need for surgery.</p><p>Specialized schooling arrangements are typically necessary for children with <i>PLP1</i> disorders. Developmental assessments can accurately assess a child's capabilities, which may be greater than is apparent because of severe motor deficits. Electronic or other communication devices may facilitate communication especially in children with visual and auditory impairment.</p></div><div id="pmd.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Proper wheelchair seating and physical therapy may help prevent scoliosis. Speech and swallowing evaluations can help prevent or reduce aspiration and identify patients who may need a feeding tube for safer and/or adequate nutrition and hydration.</p></div><div id="pmd.Surveillance"><h3>Surveillance</h3><p>Semiannual to annual neurologic and physical medicine evaluation is indicated to monitor developmental progress during childhood and to monitor and treat spasticity and orthopedic complications as needed.</p></div><div id="pmd.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Elevated body temperature, as with fever, may cause neurologic signs and symptoms to transiently worsen.</p></div><div id="pmd.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#pmd.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="pmd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>CNS stem cells were transplanted into brains of individuals with PMD in a US FDA-approved Phase I trial [<a class="bk_pop" href="#pmd.REF.gupta.2012.155ra137">Gupta et al 2012</a>]. The procedure was well tolerated, however minimal evidence of myelination was thought to be present in the transplanted regions. Several years later, the situation was unchanged [<a class="bk_pop" href="#pmd.REF.gupta.2019.254">Gupta et al 2019</a>].</p><p>Pharmacologic agents that lower expression of <i>PLP1</i> should be of theoretic benefit in individuals with extra copies of <i>PLP1</i>, as well as those with pathogenic variants associated with protein overexpression. Gene therapy using inhibitory RNA may be efficient; care should be taken to ascertain the right amount of <i>PLP1</i> expression, as abolishing <i>PLP1</i> expression altogether would lead to the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome.</p><p>Several interventions had positive effects in mouse models (e.g., ketogenic diet, cholesterol supplementation) and/or cell models of PMD (e.g., deferiprone) [<a class="bk_pop" href="#pmd.REF.saher.2012.1130">Saher et al 2012</a>, <a class="bk_pop" href="#pmd.REF.nobuta.2019.531">Nobuta et al 2019</a>, <a class="bk_pop" href="#pmd.REF.stumpf.2019.147">Stumpf et al 2019</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="pmd.Genetic_Counseling"><h2 id="_pmd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="pmd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>The <i>PLP1</i> disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="pmd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have the disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.</div></li><li class="half_rhythm"><div>In a family with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, the mother of an affected male is an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> and may manifest mild-to-moderate signs of the disease. Note: If a woman has more than one affected child and no other affected relatives and if the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in her leukocyte DNA, she most likely has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li><li class="half_rhythm"><div>In most families, the mother of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> regardless of family history.</div></li><li class="half_rhythm"><div>If a male is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (i.e., he represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case), the mother may be a <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> or the affected male may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, in which case the mother is not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> [<a class="bk_pop" href="#pmd.REF.hodes.1998.248">Hodes et al 1998</a>, <a class="bk_pop" href="#pmd.REF.grossi.2011.40">Grossi et al 2011</a>].</div></li></ul><p><b>Sibs of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs depends on the genetic status of the mother:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%.</div><ul><li class="half_rhythm"><div>Males who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Significant intrafamilial clinical variability is uncommon in <i>PLP1</i> disorders; still, families in which males have had a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are at risk of having affected offspring who may display a more severe phenotype.</div></li><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> will be heterozygotes and may manifest mild-to-moderate signs of the disorder. Female sibs are more likely to develop neurologic signs if the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males is relatively mild (complicated or pure spastic paraparesis) [<a class="bk_pop" href="#pmd.REF.hurst.2006.371">Hurst et al 2006</a>]. The risk to a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> female of being clinically affected is highest when the brother has the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> syndrome, and lowest when he has a <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a>. Heterozygous females with <i>PLP1</i> duplication have been reported to have favorably skewed X inactivation [<a class="bk_pop" href="#pmd.REF.woodward.2000.449">Woodward et al 2000</a>].</div></li></ul></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of the mother, the risk to sibs is greater than that of the general population because of the possibility of maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#pmd.REF.woodward.2003.15">Woodward et al 2003</a>].</div></li></ul><p><b>Offspring of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Males with typical PMD do not reproduce.</div></li><li class="half_rhythm"><div>Males with SPG2 may be able to father children. Affected males transmit the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to:</div><ul><li class="half_rhythm"><div class="half_rhythm">All of their daughters, who may manifest mild-to-moderate signs of the disease;</div><div class="half_rhythm">Note: <i>PLP1</i> alleles that cause relatively mild neurologic signs in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males are more likely to be associated with neurologic manifestations in <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females.</div></li><li class="half_rhythm"><div class="half_rhythm">None of their sons.</div></li></ul></li></ul><p><b>Other family members of a male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s maternal aunts and their offspring may be at risk of being <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, and manifesting mild-to-moderate signs of the disease, or of being <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> and <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> (depending on their gender, family relationship, and the genetic status of the proband's mother).</div></li><li class="half_rhythm"><div>Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> are more likely to have neurologic signs (usually adult-onset spastic paraparesis) if <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males in their family have a less severe syndrome.</div></li></ul></div><div id="pmd.Heterozygote_Detection"><h3>Heterozygote Detection</h3><p>Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p>Note: (1) Females who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for this <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> disorder are usually neurologically normal but may manifest mild-to-moderate signs of the disease. (2) Identification of female heterozygotes requires either (a) prior identification of the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family or, (b) if an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male is not available for testing, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> first by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and if no pathogenic variant is identified, by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div><div id="pmd.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Phenotypic variability.</b> It is important for couples at risk to be aware that varying phenotypes can coexist in the same kindred or sibship; thus, families in which males have had a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are at risk of having <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> offspring who may display a more severe phenotype.</p><p><b>Distantly inserted duplications.</b> While distantly inserted duplications are a rare cause of <i>PLP1</i> disorders, they may raise potentially difficult <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> issues because the inheritance pattern may not be <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> [<a class="bk_pop" href="#pmd.REF.hodes.2000.14">Hodes et al 2000</a>, <a class="bk_pop" href="#pmd.REF.inoue.2002.838">Inoue et al 2002</a>].</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, or at risk of being heterozygous.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="pmd.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Testing</h3><p>Once the <i>PLP1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-testing/">preimplantation genetic testing</a> (PGT) are possible. However; the prenatal or PGT finding of a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>PLP1</i> pathogenic variant cannot be used to accurately predict clinical outcome, as varying phenotypes may coexist in the same kindred or sibship; families in which males have had a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are at risk of having affected offspring with a more severe phenotype and females may be neurologically normal or manifest mild-to-moderate signs of the disease.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="pmd.Resources"><h2 id="_pmd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Pelizaeus%20Merzbacher%20disease&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Pelizaeus-Merzbacher disease</a></div></li><li class="half_rhythm"><div><b>National Institute of Neurological Disorders and Stroke (NINDS)</b></div><div>PO Box 5801</div><div>Bethesda MD 20824</div><div><b>Phone:</b> 800-352-9424 (toll-free); 301-496-5751; 301-468-5981 (TTY)</div><div><a href="https://www.ninds.nih.gov/Disorders/All-Disorders/Pelizaeus-Merzbacher-Disease-Information-Page" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Pelizaeus-Merzbacher Disease Information Page</a></div></li><li class="half_rhythm"><div><b>PMD Foundation</b></div><div>1307 White Horse Road</div><div>Suite 603</div><div>Voorhees NJ 08043</div><div><b>Phone:</b> 302-383-7748; 609-443-9623</div><div><b>Email:</b> donhobson@pmdfoundation.org; jeffleonard@pmdfoundation.org</div><div><a href="http://www.pmdfoundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.pmdfoundation.org</a></div></li><li class="half_rhythm"><div><b>European Leukodystrophy Association (ELA)</b></div><div>2, rue Mi-les-Vignes</div><div>B.P. 61024</div><div>Laxou Cedex 54521</div><div>France</div><div><b>Phone:</b> 03833093 34</div><div><b>Fax:</b> 03833000 68</div><div><b>Email:</b> ela@ela-asso.com</div><div><a href="http://www.ela-asso.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ela-asso.com</a></div></li><li class="half_rhythm"><div><b>Leukodystrophy Australia</b></div><div>P O Box 2550</div><div>Mount Waverley Victoria 3149</div><div>Australia</div><div><b>Phone:</b> 1800-141-400 (toll free)</div><div><b>Email:</b> info@leuko.org.au</div><div><a href="http://www.leuko.org.au/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.leuko.org.au</a></div></li><li class="half_rhythm"><div><b>United Leukodystrophy Foundation (ULF)</b></div><div>224 North Second Street</div><div>Suite 2</div><div>DeKalb IL 60115</div><div><b>Phone:</b> 800-728-5483 (toll-free); 815-748-3211</div><div><b>Fax:</b> 815-748-0844</div><div><b>Email:</b> office@ulf.org</div><div><a href="http://www.ulf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ulf.org</a></div></li><li class="half_rhythm"><div><b>Myelin Disorders Bioregistry Project</b></div><div><b>Email:</b> myelindisorders@cnmc.org</div><div><a href="https://www.chop.edu/research/myelin-disorders-biorepository-project" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myelin Disorders Bioregistry Project</a></div></li></ul></div><div id="pmd.Molecular_Genetics"><h2 id="_pmd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="pmd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>PLP1 Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_pmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_pmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_pmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_pmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_pmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_pmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_pmd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5354" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>PLP1</i></a></td><td headers="hd_b_pmd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5354" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq22<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_pmd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P60201" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myelin proteolipid protein</a></td><td headers="hd_b_pmd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/PLP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PLP1 @ LOVD</a><br /><a href="http://reseq.biosciencedbc.jp/resequence/GeneDetail.do?targetId=9&#x00026;geneId=EG5354" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HSP mutation database (PLP1)</a></td><td headers="hd_b_pmd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=PLP1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PLP1</a></td><td headers="hd_b_pmd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=PLP1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PLP1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="pmd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="pmd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for PLP1 Disorders (<a href="/omim/300401,312080,312920" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300401" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300401</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTEOLIPID PROTEIN 1; PLP1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/312080" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">312080</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PELIZAEUS-MERZBACHER DISEASE; PMD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/312920" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">312920</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPASTIC PARAPLEGIA 2, X-LINKED; SPG2</td></tr></tbody></table></div></div><div id="pmd.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><b>Introduction.</b>
<i>PLP1</i> encodes myelin proteolipid protein 1 (PLP1), which is the predominant protein constituent of central nervous system (CNS) myelin, constituting approximately 50% of the myelin protein mass. An additional <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>, the isoform DM20, which lacks the <i>PLP1</i>-specific <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> encoded by amino acids 117-151, is also encoded by <i>PLP1</i>. PLP1 and DM20 are both transmembrane proteins that span the lipid bilayer four times and are anchored to cell membranes through covalent acyl linkages to fatty acids. There is evidence that PLP1 cements adjacent leaflets of myelin; however, additional or alternative functions are also possible [<a class="bk_pop" href="#pmd.REF.griffiths.1998.344">Griffiths et al 1998</a>, <a class="bk_pop" href="#pmd.REF.aggarwal.2011.585">Aggarwal et al 2011</a>].</p><p>PLP1, but not DM20, has been shown to form dimers at an intracellular cysteine residue [<a class="bk_pop" href="#pmd.REF.daffu.2012.144">Daffu et al 2012</a>]. This dimerization may contribute to the molecular pathogenesis of PMD, both in patients with indels and those with duplications.</p><p><b>Mechanism of disease causation.</b> Duplication of <i>PLP1</i> results in overexpression of PLP1, leading to dysfunction and death of oligodendrocytes, the myelin-forming cells in the CNS [<a class="bk_pop" href="#pmd.REF.griffiths.1998.344">Griffiths et al 1998</a>, <a class="bk_pop" href="#pmd.REF.yool.2000.987">Yool et al 2000</a>]. Increased PLP1 expression results in mislocalization of PLP1 along with cholesterol and lipids to the late endosomal/lysosomal compartment [<a class="bk_pop" href="#pmd.REF.simons.2000.143">Simons et al 2000</a>]. The association of hypomyelination and subsequent axonal injury in PMD and other leukodystrophies is reviewed by <a class="bk_pop" href="#pmd.REF.mar.2010.239">Mar &#x00026; Noetzel [2010]</a>.</p><p>Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants cause misfolding of PLP1 or DM20. These misfolded proteins are retained in the endoplasmic reticulum (ER), failing to be incorporated into the cell membrane where they activate the unfolded protein response [<a class="bk_pop" href="#pmd.REF.southwood.2002.585">Southwood et al 2002</a>, <a class="bk_pop" href="#pmd.REF.inoue.2017.7">Inoue 2017</a>]. In a severe mouse model, the jimpy mouse, there is ER stress and subsequent cell death when oligodendrocyte progenitors mature [<a class="bk_pop" href="#pmd.REF.elitt.2018.711">Elitt et al 2018</a>].</p><p>Deletion of <i>PLP1</i>, and probably other <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants, results in mild myelin defects but subsequent more severe axonal degeneration [<a class="bk_pop" href="#pmd.REF.garbern.2002.551">Garbern et al 2002</a>].</p><p>Variants in the <i>PLP1</i> specific part of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> (described as <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3B) and the adjacent <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 3 lead to hypomyelination of early myelinating structures, through decreased PLP1 expression in relation to DM20 [<a class="bk_pop" href="#pmd.REF.taube.2014.5464">Taube et al 2014</a>, <a class="bk_pop" href="#pmd.REF.kevelam.2015.648">Kevelam et al 2015</a>].</p><p><b><i>PLP1</i>-specific laboratory considerations.</b> Some deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variants outside of the immediate splice junction regions have been associated with <i>PLP1</i> disorders [<a class="bk_pop" href="#pmd.REF.taube.2014.5464">Taube et al 2014</a>, <a class="bk_pop" href="#pmd.REF.kevelam.2015.648">Kevelam et al 2015</a>]. Of note, the complete conservation of amino acid sequence between rodent and human <i>PLP1</i> suggests little tolerance for sequence variation.</p><div id="pmd.T.notable_plp1_pathogenic_variants" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Notable <i>PLP1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1182/table/pmd.T.notable_plp1_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pmd.T.notable_plp1_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide<br />Change</th><th id="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted<br />Protein Change</th><th id="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000533.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000533<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000524.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000524<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.453+159G&#x0003e;A</td><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_4" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;">Deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variants associated<br />w/HEMS [<a class="bk_pop" href="#pmd.REF.kevelam.2015.648">Kevelam et al 2015</a>]</td></tr><tr><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.453+164G&#x0003e;A</td><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.454-312C&#x0003e;G</td><td headers="hd_h_pmd.T.notable_plp1_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="pmd.References"><h2 id="_pmd_References_">References</h2><div id="pmd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.aggarwal.2011.585">Aggarwal S, Yurlova L, Simons M. Central nervous system myelin: structure, synthesis and assembly. <span><span class="ref-journal">Trends Cell Biol. </span>2011;<span class="ref-vol">21</span>:585–93.</span> [<a href="/pubmed/21763137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21763137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.barkovich.2005.311">Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelination. <span><span class="ref-journal">J Inherit Metab Dis. </span>2005;<span class="ref-vol">28</span>:311–43.</span> [<a href="/pubmed/15868466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15868466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.boespflugtanguy.1994.461">Boespflug-Tanguy O, Mimault C, Melki J, Cavagna A, Giraud G, Pham Dinh D, Dastugue B, Dautigny A. Genetic homogeneity of Pelizaeus-Merzbacher disease: tight linkage to the proteolipoprotein locus in 16 affected families. PMD Clinical Group. <span><span class="ref-journal">Am J Hum Genet. </span>1994;<span class="ref-vol">55</span>:461–7.</span> [<a href="/pmc/articles/PMC1918422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1918422</span></a>] [<a href="/pubmed/7915877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7915877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.bonavita.2001.785">Bonavita S, Schiffmann R, Moore DF, Frei K, Choi B, Patronas MD N, Virta A, Boespflug-Tanguy O, Tedeschi G. Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:785–8.</span> [<a href="/pubmed/11274318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11274318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.bonkowsky.2010.718">Bonkowsky JL, Nelson C, Kingston JL, Filloux FM, Mundorff MB, Srivastava R. The burden of inherited leukodystrophies in children. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:718–25.</span> [<a href="/pmc/articles/PMC2931652/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2931652</span></a>] [<a href="/pubmed/20660364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20660364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.boulloche.1986.233">Boulloche J, Aicardi J. Pelizaeus-Merzbacher disease: clinical and nosological study. <span><span class="ref-journal">J Child Neurol. </span>1986;<span class="ref-vol">1</span>:233–9.</span> [<a href="/pubmed/3598129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3598129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.cailloux.2000.837">Cailloux F, Gauthier-Barichard F, Mimault C, Isabelle V, Courtois V, Giraud G, Dastugue B, Boespflug-Tanguy O. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. <span><span class="ref-journal">Eur J Hum Genet. </span>2000;<span class="ref-vol">8</span>:837–45.</span> [<a href="/pubmed/11093273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11093273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.combes.2006.31">Combes P, Bonnet-Dupeyron MN, Gauthier-Barichard F, Schiffmann R, Bertini E, Rodriguez D, Armour JA, Boespflug-Tanguy O, Vaurs-Barri&#x000e8;re C. PLP1 and GPM6B intragenic copy number analysis by MAPH in 262 patients with hypomyelinating leukodystrophies: identification of one partial triplication and two partial deletions of PLP1. <span><span class="ref-journal">Neurogenetics. </span>2006;<span class="ref-vol">7</span>:31–7.</span> [<a href="/pubmed/16416265" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16416265</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.daffu.2012.144">Daffu G, Sohi J, Kamholz J. Proteolipid protein dimerization at cysteine 108: Implications for protein structure. <span><span class="ref-journal">Neurosci Res. </span>2012;<span class="ref-vol">74</span>:144–55.</span> [<a href="/pubmed/22902553" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22902553</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.elitt.2018.711">Elitt MS, Shick HE, Madhavan M, Allan KC, Clayton BLL, Weng C, Miller TE, Factor DC, Barbar L, Nawash BS, Nevin ZS, Lager AM, Li Y, Jin F, Adams DJ, Tesar PJ. Chemical screening identifies enhancers of mutant oligodendrocyte survival and unmasks a distinct pathological phase in Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Stem Cell Reports. </span>2018;<span class="ref-vol">11</span>:711–26.</span> [<a href="/pmc/articles/PMC6135742/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6135742</span></a>] [<a href="/pubmed/30146490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30146490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.garbern.2002.1033">Garbern J, Hobson G. Prenatal diagnosis of Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Prenat Diagn. </span>2002;<span class="ref-vol">22</span>:1033–5.</span> [<a href="/pubmed/12424770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12424770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.garbern.2002.551">Garbern JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, Nave KA, Sistermans EA, van der Knaap MS, Bird TD, Shy ME, Kamholz JA, Griffiths IR. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. <span><span class="ref-journal">Brain. </span>2002;<span class="ref-vol">125</span>:551–61.</span> [<a href="/pubmed/11872612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11872612</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.griffiths.1998.344">Griffiths I, Klugmann M, Anderson T, Thomson C, Vouyiouklis D, Nave KA. Current concepts of PLP and its role in the nervous system. <span><span class="ref-journal">Microsc Res Tech. </span>1998;<span class="ref-vol">41</span>:344–58.</span> [<a href="/pubmed/9672418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9672418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.grossi.2011.40">Grossi S, Regis S, Biancheri R, Mort M, Lualdi S, Bertini E, Uziel G, Boespflug-Tanguy O, Simonati A, Corsolini F, Demir E, Marchiani V, Percesepe A, Stanzial F, Rossi A, Vaurs-Barri&#x000e8;re C, Cooper DN, Filocamo M. Molecular genetic analysis of the PLP1 gene in 38 families with PLP1-related disorders: identification and functional characterization of 11 novel PLP1 mutations. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2011;<span class="ref-vol">6</span>:40.</span> [<a href="/pmc/articles/PMC3125326/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3125326</span></a>] [<a href="/pubmed/21679407" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21679407</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.gupta.2019.254">Gupta N, Henry RG, Kang S-M, Strober J, Lim DA, Ryan T, Perry R, Farrell J, Ulman M, Rajalingam R, Gage A, Huhn SL, Barkovich AJ, Rowitch DH. Long-term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Stem Cell Reports. </span>2019;<span class="ref-vol">13</span>:254–61.</span> [<a href="/pmc/articles/PMC6700500/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6700500</span></a>] [<a href="/pubmed/31378671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31378671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.gupta.2012.155ra137">Gupta N, Henry RG, Strober J, Kang SM, Lim DA, Bucci M, Caverzasi E, Gaetano L, Mandelli ML, Ryan T, Perry R, Farrell J, Jeremy RJ, Ulman M, Huhn SL, Barkovich AJ, Rowitch DH. Neural stem cell engraftment and myelination in the human brain. <span><span class="ref-journal">Sci Transl Med. </span>2012;<span class="ref-vol">4</span>:155ra137</span> [<a href="/pmc/articles/PMC3893824/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3893824</span></a>] [<a href="/pubmed/23052294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23052294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.harting.2019.903">Harting I, Karch S, Moog U, Seitz A, Pouwels P, Wolf N. Oculodentodigital dysplasia: a hypomyelinating leukodystrophy with a characteristic MRI pattern of brain stem involvement. <span><span class="ref-journal">Am J Neuroradiol. </span>2019;<span class="ref-vol">40</span>:903–907.</span> [<a href="/pubmed/31048294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31048294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.heim.1997.475">Heim P, Claussen M, Hoffmann B, Conzelmann E, Gartner J, Harzer K, Hunneman DH, Kohler W, Kurlemann G, Kohlschutter A. Leukodystrophy incidence in Germany. <span><span class="ref-journal">Am J Med Genet. </span>1997;<span class="ref-vol">71</span>:475–8.</span> [<a href="/pubmed/9286459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9286459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.hobson.2002.2045a">Hobson GM, Ritterson CM, Bird TD, Raskind WH, Garbern JY, Sperle K. Deletion breakpoint analysis in a patient with Pelizaeus-Merzbacher disease (PMD) and comparison with duplications. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:2045A.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.hodes.1998.248">Hodes ME, Aydanian A, Dlouhy SR, Whelan DT, Heshka T, Ronen G. A de novo mutation (C755T; Ser252Phe) in exon 6 of the proteolipid protein gene responsible for Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Clin Genet. </span>1998;<span class="ref-vol">54</span>:248–9.</span> [letter] [<a href="/pubmed/9788732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9788732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.hodes.1993.383">Hodes ME, Pratt VM, Dlouhy SR. Genetics of Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Dev Neurosci. </span>1993;<span class="ref-vol">15</span>:383–94.</span> [<a href="/pubmed/7530633" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7530633</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.hodes.2000.14">Hodes ME, Woodward K, Spinner NB, Emanuel BS, Enrico-Simon A, Kamholz J, Stambolian D, Zackai EH, Pratt VM, Thomas IT, Crandall K, Dlouhy SR, Malcolm S. Additional copies of the proteolipid protein gene causing Pelizaeus-Merzbacher disease arise by separate integration into the X chromosome. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">67</span>:14–22.</span> [<a href="/pmc/articles/PMC1287072/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1287072</span></a>] [<a href="/pubmed/10827108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10827108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.hodes.1999.132">Hodes ME, Zimmerman AW, Aydanian A, Naidu S, Miller NR, Garcia Oller JL, Barker B, Aleck KA, Hurley TD, Dlouhy SR. Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus- Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2). <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">82</span>:132–9.</span> [<a href="/pubmed/9934976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9934976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.hurst.2006.371">Hurst S, Garbern J, Trepanier A, Gow A. Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Genet Med. </span>2006;<span class="ref-vol">8</span>:371–8.</span> [<a href="/pubmed/16778599" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16778599</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.ida.2003.557">Ida T, Miharu N, Hayashitani M, Shimokawa O, Harada N, Samura O, Kubota T, Niikawa N, Matsumoto N. Functional disomy for Xq22-q23 in a girl with complex rearrangements of chromosomes 3 and X. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">120A</span>:557–61.</span> [<a href="/pubmed/12884439" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12884439</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.inoue.2002.838">Inoue K, Osaka H, Thurston VC, Clarke JT, Yoneyama A, Rosenbarker L, Bird TD, Hodes ME, Shaffer LG, Lupski JR. Genomic rearrangements resulting in PLP1 deletion occur by nonhomologous end joining and cause different dysmyelinating phenotypes in males and females. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:838–53.</span> [<a href="/pmc/articles/PMC378540/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC378540</span></a>] [<a href="/pubmed/12297985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12297985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.inoue.2001.747">Inoue K, Tanaka H, Scaglia F, Araki A, Shaffer LG, Lupski JR. Compensating for central nervous system dysmyelination: females with a proteolipid protein gene duplication and sustained clinical improvement. <span><span class="ref-journal">Ann Neurol. </span>2001;<span class="ref-vol">50</span>:747–54.</span> [<a href="/pubmed/11761472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11761472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.inoue.2017.7">Inoue K. Cellular pathology of Pelizaeus-Merzbacher disease involving chaperones associated with endoplasmic reticulum stress. <span><span class="ref-journal">Front Mol Biosci. </span>2017;<span class="ref-vol">4</span>:7.</span> [<a href="/pmc/articles/PMC5323380/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5323380</span></a>] [<a href="/pubmed/28286750" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28286750</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.keogh.2017.451">Keogh MJ, Jaiser SR, Steele HE, Horvath R, Chinnery PF, Baker MR. PLP1 mutations and central demyelination: Evidence from electrophysiologic phenotyping in female manifesting carriers. <span><span class="ref-journal">Neurol Clin Pract. </span>2017;<span class="ref-vol">7</span>:451–4.</span> [<a href="/pmc/articles/PMC5874467/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5874467</span></a>] [<a href="/pubmed/29620084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29620084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.kevelam.2015.648">Kevelam SH, Taube JR, van Spaendonk RM, Bertini E, Sperle K, Tarnopolsky M, Tonduti D, Valente EM, Travaglini L, Sistermans EA, Bernard G, Catsman-Berrevoets CE, van Karnebeek CD, &#x000d8;stergaard JR, Friederich RL, Fawzi Elsaid M, Schieving JH, Tarailo-Graovac M, Orcesi S, Steenweg ME, van Berkel CG, Waisfisz Q, Abbink TE, van der Knaap MS, Hobson GM, Wolf NI. Altered PLP1 splicing causes hypomyelination of early myelinating structures. <span><span class="ref-journal">Ann Clin Transl Neurol. </span>2015;<span class="ref-vol">2</span>:648–61.</span> [<a href="/pmc/articles/PMC4479525/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4479525</span></a>] [<a href="/pubmed/26125040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26125040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.lee.2007.1235">Lee JA, Carvalho CM, Lupski JR. A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. <span><span class="ref-journal">Cell. </span>2007;<span class="ref-vol">131</span>:1235–47.</span> [<a href="/pubmed/18160035" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18160035</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.lee.2006.398">Lee JA, Madrid RE, Sperle K, Ritterson CM, Hobson GM, Garbern J, Lupski JR, Inoue K. Spastic paraplegia type 2 associated with axonal neuropathy and apparent PLP1 position effect. <span><span class="ref-journal">Ann Neurol. </span>2006;<span class="ref-vol">59</span>:398–403.</span> [<a href="/pubmed/16374829" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16374829</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.mar.2010.239">Mar S, Noetzel M. Axonal damage in leukodystrophies. <span><span class="ref-journal">Pediatr Neurol. </span>2010;<span class="ref-vol">42</span>:239–42.</span> [<a href="/pubmed/20304325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20304325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.masliahplanchon.2015.77">Masliah-Planchon J, Dupont C, Vartzelis G, Trimouille A, Eymard-Pierre E, Gay-Bellile M, Renaldo F, Dorboz I, Pagan C, Quentin S, Elmaleh M, Kotsogianni C, Konstantelou E, Drunat S, Tabet AC, Boespflug-Tanguy O. Insertion of an extra copy of Xq22.2 into 1p36 results in functional duplication of the PLP1 gene in a girl with classical Pelizaeus-Merzbacher disease. <span><span class="ref-journal">BMC Med Genet. </span>2015;<span class="ref-vol">16</span>:77.</span> [<a href="/pmc/articles/PMC4557901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4557901</span></a>] [<a href="/pubmed/26329556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26329556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.miyake.2017.185">Miyake N, Wolf NI, Cayami FK, Crawford J, Bley A, Bulas D, Conant A, Bent SJ, Gripp KW, Hahn A, Humphray S, Kimura-Ohba S, Kingsbury Z, Lajoie BR, Lal D, Micha D, Pizzino A, Sinke RJ, Sival D, Stolte-Dijkstra I, Superti-Furga A, Ulrick N, Taft RJ, Ogata T, Ozono K, Matsumoto N, Neubauer BA, Simons C, Vanderver A. X-linked hypomyelination with spondylometaphyseal dysplasia (H-SMD) associated with mutations in AIFM1. <span><span class="ref-journal">Neurogenetics. </span>2017;<span class="ref-vol">18</span>:185–94.</span> [<a href="/pmc/articles/PMC5705759/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5705759</span></a>] [<a href="/pubmed/28842795" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28842795</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.muncke.2004.e121">Muncke N, Wogatzky BS, Breuning M, Sistermans EA, Endris V, Ross M, Vetrie D, Catsman-Berrevoets CE, Rappold G. Position effect on PLP1 may cause a subset of Pelizaeus-Merzbacher disease symptoms. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:e121</span> [<a href="/pmc/articles/PMC1735635/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735635</span></a>] [<a href="/pubmed/15591263" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15591263</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.nobuta.2019.531">Nobuta H, Yang N, Ng YH, Marro SG, Sabeur K, Chavali M, Stockley JH, Killilea DW, Walter PB, Zhao C, Huie P Jr, Goldman SA, Kriegstein AR, Franklin RJM, Rowitch DH, Wernig M. Oligodendrocyte death in Pelizaeus-Merzbacher disease is rescued by iron chelation. <span><span class="ref-journal">Cell Stem Cell. </span>2019;<span class="ref-vol">25</span>:531–41.</span> [<a href="/pubmed/31585094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31585094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.plecko.2003.127">Plecko B, Stockler-Ipsiroglu S, Gruber S, Mlynarik V, Moser E, Simbrunner J, Ebner F, Bernert G, Harrer G, Gal A, Prayer D. Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype. <span><span class="ref-journal">Neuropediatrics. </span>2003;<span class="ref-vol">34</span>:127–36.</span> [<a href="/pubmed/12910435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12910435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.raskind.1991.1355">Raskind WH, Williams CA, Hudson LD, Bird TD. Complete deletion of the proteolipid protein gene (PLP) in a family with X-linked Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Am J Hum Genet. </span>1991;<span class="ref-vol">49</span>:1355–60.</span> [<a href="/pmc/articles/PMC1686465/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1686465</span></a>] [<a href="/pubmed/1720927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1720927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.saher.2012.1130">Saher G, Rudolphi F, Corthals K, Ruhwedel T, Schmidt K-F, L&#x000f6;wel S, Dibaj P, Barrette B, M&#x000f6;bius W, Nave KA. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. <span><span class="ref-journal">Nat Med. </span>2012;<span class="ref-vol">18</span>:1130–5.</span> [<a href="/pubmed/22706386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22706386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.sarret.2016.706">Sarret C, Lemaire JJ, Tonduti D, Sontheimer A, Coste J, Pereira B, Feschet F, Roche B, Boespflug-Tanguy O. Time-course of myelination and atrophy on cerebral imaging in 35 patients with PLP1-related disorders. <span><span class="ref-journal">Dev Med Child Neurol. </span>2016;<span class="ref-vol">58</span>:706–13.</span> [<a href="/pubmed/26786043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26786043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.scala.2019.268">Scala M, Traverso M, Capra V, Vari MS, Severino M, Grossi S, Zara F, Striano P, Minetti C. Pelizaeus-Merzbacher disease due to PLP1 frameshift mutation in a female with nonrandom skewed X-chromosome inactivation. <span><span class="ref-journal">Neuropediatrics. </span>2019;<span class="ref-vol">50</span>:268–70.</span> [<a href="/pubmed/31137068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31137068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.seeman.2003.95">Seeman P, Krsck P, Namestkova K, Malikova M, Belsan T, Proskova M. Pelizaeus-Merzbacher's disease (PMD) - detection of the most frequent mutation of the proteolipid protein gene in Czech patients and famillies with the classical form of PMD. <span><span class="ref-journal">Ceska Slovenska Neurol Neurochir. </span>2003;<span class="ref-vol">66</span>:95–104.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.shy.2003.354">Shy ME, Hobson G, Jain M, Boespflug-Tanguy O, Garbern J, Sperle K, Li W, Gow A, Rodriguez D, Bertini E, Mancias P, Krajewski K, Lewis R, Kamholz J. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. <span><span class="ref-journal">Ann Neurol. </span>2003;<span class="ref-vol">53</span>:354–65.</span> [<a href="/pmc/articles/PMC4744322/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4744322</span></a>] [<a href="/pubmed/12601703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12601703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.simons.2000.143">Simons M, Kramer EM, Thiele C, Stoffel W, Trotter J. Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. <span><span class="ref-journal">J Cell Biol. </span>2000;<span class="ref-vol">151</span>:143–54.</span> [<a href="/pmc/articles/PMC2189802/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2189802</span></a>] [<a href="/pubmed/11018060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11018060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.sistermans.1998.1749">Sistermans EA, de Coo RF, De Wijs IJ, Van Oost BA. Duplication of the proteolipid protein gene is the major cause of Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Neurology. </span>1998;<span class="ref-vol">50</span>:1749–54.</span> [<a href="/pubmed/9633722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9633722</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.sivakumar.1999.680">Sivakumar K, Sambuughin N, Selenge B, Nagle JW, Baasanjav D, Hudson LD, Goldfarb LG. Novel exon 3B proteolipid protein gene mutation causing late-onset spastic paraplegia type 2 with variable penetrance in female family members. <span><span class="ref-journal">Ann Neurol. </span>1999;<span class="ref-vol">45</span>:680–3.</span> [<a href="/pubmed/10319897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10319897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.southwood.2002.585">Southwood CM, Garbern J, Jiang W, Gow A. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Neuron. </span>2002;<span class="ref-vol">36</span>:585–96.</span> [<a href="/pmc/articles/PMC4603660/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4603660</span></a>] [<a href="/pubmed/12441049" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12441049</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.steenweg.2010.2971">Steenweg ME, Vanderver A, Blaser S, Bizzi A, de Koning TJ, Mancini GM, van Wieringen WN, Barkhof F, Wolf NI, van der Knaap MS. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:2971–82.</span> [<a href="/pmc/articles/PMC3589901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3589901</span></a>] [<a href="/pubmed/20881161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20881161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.stumpf.2019.147">Stumpf SK, Berghoff SA, Trevisiol A, Spieth L, D&#x000fc;king T, Schneider LV, Schlaphoff L, Dreha-Kulaczewski S, Bley A, Burfeind D, Kusch K, Mitkovski M, Ruhwedel T, Guder P, R&#x000f6;hse H, Denecke J, G&#x000e4;rtner J, M&#x000f6;bius W, Nave KA, Saher G. Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus&#x02013;Merzbacher disease. <span><span class="ref-journal">Acta Neuropathol. </span>2019;<span class="ref-vol">138</span>:147–61.</span> [<a href="/pmc/articles/PMC6570703/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6570703</span></a>] [<a href="/pubmed/30919030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30919030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.taube.2014.5464">Taube JR, Sperle K, Banser L, Seeman P, Cavan BC, Garbern JY, Hobson GM. PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:5464–78.</span> [<a href="/pmc/articles/PMC4168831/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4168831</span></a>] [<a href="/pubmed/24890387" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24890387</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.van_der_knaap.2019.962">van der Knaap MS, Schiffmann R, Mochel F, Wolf NI. Diagnosis, prognosis, and treatment of leukodystrophies. <span><span class="ref-journal">Lancet Neurol. </span>2019;<span class="ref-vol">18</span>:962–72.</span> [<a href="/pubmed/31307818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31307818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.van_haren.2015.516">Van Haren K, Bonkowsky JL, Bernard G, Murphy JL, Pizzino A, Helman G, Suhr D, Waggoner J, Hobson D, Vanderver A, Patterson MC. Consensus statement on preventive and symptomatic care of leukodystrophy patients. <span><span class="ref-journal">Mol Genet Metab. </span>2015;<span class="ref-vol">114</span>:516–26.</span> [<a href="/pubmed/25577286" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25577286</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.vaursbarri_re.2003.769">Vaurs-Barri&#x000e8;re C, Wong K, Weibel TD, Abu-Asab M, Weiss MD, Kaneski CR, Mixon TH, Bonavita S, Creveaux I, Heiss JD, Tsokos M, Goldin E, Quarles RH, Boespflug-Tanguy O, Schiffmann R. Insertion of mutant proteolipid protein results in missorting of myelin proteins. <span><span class="ref-journal">Ann Neurol. </span>2003;<span class="ref-vol">54</span>:769–80.</span> [<a href="/pmc/articles/PMC4294275/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4294275</span></a>] [<a href="/pubmed/14681886" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14681886</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.wolf.2014.134">Wolf NI, Salomons GS, Rodenburg RJ, Pouwels PJ, Schieving JH, Derks TG, Fock JM, Rump P, van Beek DM, van der Knaap MS, Waisfisz Q. Mutations in RARS cause hypomyelination. <span><span class="ref-journal">Ann Neurol. </span>2014;<span class="ref-vol">76</span>:134–9.</span> [<a href="/pubmed/24777941" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24777941</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.wolf.2005.743">Wolf NI, Sistermans EA, Cundall M, Hobson GM, Davis-Williams AP, Palmer R, Stubbs P, Davies S, Endziniene M, Wu Y, Chong WK, Malcolm S, Surtees R, Garbern JY, Woodward KJ. Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:743–51.</span> [<a href="/pubmed/15689360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15689360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.woodward.2003.15">Woodward K, Cundall M, Palmer R, Surtees R, Winter RM, Malcolm S. Complex chromosomal rearrangement and associated counseling issues in a family with Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Am J Med Genet. </span>2003;<span class="ref-vol">118A</span>:15–24.</span> [<a href="/pubmed/12605435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12605435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.woodward.1998.a394">Woodward K, Kendall E, Vetrie D, et al.  Variation in PLP gene duplications causing Pelizaeus-Merzbacher disease. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:A394.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.woodward.2000.449">Woodward K, Kirtland K, Dlouhy S, Raskind W, Bird T, Malcolm S, Abeliovich D. X inactivation phenotype in carriers of Pelizaeus-Merzbacher disease: skewed in carriers of a duplication and random in carriers of point mutations. <span><span class="ref-journal">Eur J Hum Genet. </span>2000;<span class="ref-vol">8</span>:449–54.</span> [<a href="/pubmed/10878666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10878666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.woodward.2005.966">Woodward KJ, Cundall M, Sperle K, Sistermans EA, Ross M, Howell G, Gribble SM, Burford DC, Carter NP, Hobson DL, Garbern JY, Kamholz J, Heng H, Hodes ME, Malcolm S, Hobson GM. Heterogeneous duplications in patients with Pelizaeus-Merzbacher disease suggest a mechanism of coupled homologous and nonhomologous recombination. <span><span class="ref-journal">Am J Hum Genet. </span>2005;<span class="ref-vol">77</span>:966–87.</span> [<a href="/pmc/articles/PMC1285180/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1285180</span></a>] [<a href="/pubmed/16380909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16380909</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.yan.2019.996">Yan H, Helman G, Murthy SE, Ji H, Crawford J, Kubisiak T, Bent SJ, Xiao J, Taft RJ, Coombs A, Wu Y, Pop A, Li D, de Vries LS, Jiang Y, Salomons GS, van der Knaap MS, Patapoutian A, Simons C, Burmeister M, Wang J, Wolf NI. Heterozygous variants in the mechanosensitive ion channel TMEM63A result in transient hypomyelination during infancy. <span><span class="ref-journal">Am J Hum Genet. </span>2019;<span class="ref-vol">105</span>:996–1004.</span> [<a href="/pmc/articles/PMC6848986/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6848986</span></a>] [<a href="/pubmed/31587869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31587869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.yiu.2009.2171">Yiu EM, Farrell SA, Soman T. Classic Pelizaeus-Merzbacher disease in a girl with an unbalanced chromosomal translocation and functional duplication of PLP1. <span><span class="ref-journal">Mov Disord. </span>2009;<span class="ref-vol">24</span>:2171–2.</span> [<a href="/pubmed/19705472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19705472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pmd.REF.yool.2000.987">Yool DA, Edgar JM, Montague P, Malcolm S. The proteolipid protein gene and myelin disorders in man and animal models. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:987–92.</span> [<a href="/pubmed/10767322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10767322</span></a>]</div></li></ul></div></div><div id="pmd.Chapter_Notes"><h2 id="_pmd_Chapter_Notes_">Chapter Notes</h2><div id="pmd.Acknowledgments"><h3>Acknowledgments</h3><p>The authors are grateful to the PMD Foundation, the Children's Research Center of Michigan, the Nemours Foundation, the NIH, and the PMD families.</p></div><div id="pmd.Author_History"><h3>Author History</h3><p>James Y Garbern, MD, PhD; University of Rochester Medical Center (1999-2011*)<br />Grace M Hobson, PhD (2006-present)<br />John Kamholz, MD, PhD (2013-present)<br />Karen Krajewski, MS; Wayne State University School of Medicine/Detroit Medical Center (2006-2010)<br />Rosalina ML van Spaendonk, PhD (2019-present)<br />Nicole I Wolf, MD, PhD (2019-present)</p><p>*James Y Garbern was a specialist in leukodystrophies and hereditary neurologic disorders and an internationally recognized expert on PMD. Dr Garbern died in November 2011.</p></div><div id="pmd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>19 December 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 February 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 March 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 September 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 October 2004 (jg) Revision: <a class="figpopup" href="/books/NBK1182/table/pmd.T.genes_of_interest_in_the_different/?report=objectonly" target="object" rid-figpopup="figpmdTgenesofinterestinthedifferent" rid-ob="figobpmdTgenesofinterestinthedifferent">Table 3</a></div></li><li class="half_rhythm"><div>11 June 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 March 2002 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 June 1999 (me) Review posted live</div></li><li class="half_rhythm"><div>28 January 1999 (jg) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1182</span><span class="label">PMID: <a href="/pubmed/20301361" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301361</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/eds6/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cdg-1a/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1182&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1182/?report=reader">PubReader</a></li><li><a href="/books/NBK1182/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1182" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1182" style="display:none" title="Cite this Page"><div class="bk_tt">Wolf NI, van Spaendonk RML, Hobson GM, et al. PLP1 Disorders. 1999 Jun 15 [Updated 2019 Dec 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1182/pdf/Bookshelf_NBK1182.pdf">PDF version of this page</a> (513K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#pmd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#pmd.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#pmd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#pmd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#pmd.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#pmd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#pmd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#pmd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#pmd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#pmd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#pmd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#pmd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5354[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">PLP1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1493146" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1493146" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1493146" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1493146" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22422208" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders.</a><span class="source">[Semin Neurol. 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hobson GM, Garbern JY. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Semin Neurol. 2012 Feb; 32(1):62-7. Epub 2012 Mar 15.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24501781" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Leukodystrophy Overview</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Leukodystrophy Overview<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Vanderver A, Tonduti D, Schiffmann R, Schmidt J, van der Knaap MS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24519770" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The spectrum of PLP1 gene mutations in patients with the classical form of the Pelizaeus-Merzbacher disease.</a><span class="source">[Med Wieku Rozwoj. 2013]</span><div class="brieflinkpop offscreen_noflow">The spectrum of PLP1 gene mutations in patients with the classical form of the Pelizaeus-Merzbacher disease.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hoffman-Zacharska D, Mierzewska H, Szczepanik E, Poznański J, Mazurczak T, Jakubiuk-Tomaszuk A, Mądry J, Kierdaszuk A, Bal J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Med Wieku Rozwoj. 2013 Oct-Dec; 17(4):293-300. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15627202" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2.</a><span class="source">[Neurogenetics. 2005]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Inoue K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurogenetics. 2005 Feb; 6(1):1-16. Epub 2004 Dec 31.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15450775" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A case of complicated spastic paraplegia 2 due to a point mutation in the proteolipid protein 1 gene.</a><span class="source">[J Neurol Sci. 2004]</span><div class="brieflinkpop offscreen_noflow">A case of complicated spastic paraplegia 2 due to a point mutation in the proteolipid protein 1 gene.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lee ES, Moon HK, Park YH, Garbern J, Hobson GM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurol Sci. 2004 Sep 15; 224(1-2):83-7. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301361" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301361" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc93ea39a66ee2ba353fde">PLP1 Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">PLP1 Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:27:06-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE896571DFC9378100000000003D0020&amp;ncbi_session=CE896571DFC93E91_0061SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1182%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1182&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1182/&amp;ncbi_pagename=PLP1 Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE896571DFC93E91_0061SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>